Analogues of N,N-dimethyl-4-(pyrimidin-2-yl)piperazine-1-sulfonamide possessing a free radical scavenger group (FRS), chelating groups (CHL), or both (FRS þ CHL) have been synthesized. Electrospray ionization mass spectrometry studies indicate that select members of this series bind ions in the relative order of Cu 1þ =Cu 2þ >Fe 2þ =Fe 3þ > Zn 2þ with no binding of Ca 2þ or Mg 2þ observed. In vitro evaluation of these compounds in human lens epithelial, human retinal pigmented epithelial, and human hippocampal astrocyte cell lines indicates that all analogues possessing the FRS group as well as the water-soluble vitamin E analogue 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid protect these cells against decreased cell viability and glutathione levels induced by hydrogen peroxide. In addition, those compounds possessing CHL groups also protected these cells against hydroxyl radicals generated by the Fenton reaction. These compounds are good candidates for the preventive treatment of cataract, age-related macular degeneration (AMD), and Alzheimer's dementia (AD).
Introduction
Oxidative stress damages cells and is an accepted determinant of both lifespan and health span. Oxidative stress results from the generation of reactive oxygen species (ROS a ), primarily H 2 O 2 , and is enhanced by the age-related decrease of cellular antioxidant defenses and accumulation of iron and/or copper. 1 The increased cellular presence of these redox-active metals enhance H 2 O 2 -linked ROS by generating hydroxyl radicals through the Fenton reaction. 2, 3 Age-related increases in ROS are believed to trigger biochemical cascades that lead to neurodegenerations such as AD, [4] [5] [6] retinal degenerations such as age-related macular degeneration (AMD), [7] [8] [9] [10] and cataract formation. 7, 11 While these diseases are pathologically different, studies suggest that they all undergo similar oxidative damage from ROS associated with redox-active metal ions. For example, ROS-associated Aβ in amyloid plaques, which are characteristic of AD, 4, [12] [13] [14] [15] is also present in AMD [16] [17] [18] and age-related cataract. [19] [20] [21] The oxidative pathways associated with neurodegenerations and age-related ocular diseases have been targeted as a potential therapeutic approach to the treatment of these agerelated diseases. 5 A wide variety of antioxidants have been examined to reduce ROS. These range from natural products with antioxidant properties such as aged garlic extract, curcumin, melatonin, resveratrol, Ginkgo biloba extract, green tea, vitamin C, L-carnosine, vitamin E, and cannabinoids to derivatives of lipoic acid, analogues of coenzyme Q (MitoQ), and "thiol-delivering" glutathione mimics such as tricyclodecan-9-yl xanthogenate. [22] [23] [24] [25] [26] [27] [28] [29] Some of these agents have shown limited clinical efficacy with AMD, 30, 31 but none have demonstrated clinical efficacy in reducing the clinical signs of neurodegeneration or cataract.
Reducing ROS through the chelation of redox-active metals is another approach that has been investigated; however, this approach has primarily been used to treat neurodegenerations. Examples are illustrated in Figure 1 . Of these compounds, only the iron chelator desferrioxamine (DFO, N 0 -{5-[acetyl(hydroxy)amino]pentyl}-N-[5,4-[(5-aminopentyl)-(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide) and clioquinol (5-chloro-7-iodoquinolin-8-ol) has been investigated for both neurological 32, 33 and agerelated ocular diseases. [34] [35] [36] Desferrioxamine is not orally active and does not significantly cross the blood-brain barrier. 37, 38 Clioquinol is an orally active antibiotic that was extensively used as an antibiotic in Asia in the 1960s. In 1971 it was banned in Japan after being linked to subacute myelooptic neuropathy (SMON) in over 10 000 Japanese people. Its chelating ability was subsequently identified during neurotoxicity studies 39 where it has been demonstrated to decrease Cu uptake and counteract Cu efflux activities of the amyloid precursor protein of AD, 40 disaggregate the metal ioninduced aggregates of Aβ , and retard fibril growth through a Zn(II) clioquinol complex formation. 41 Its efficacy has been demonstrated in vitro, in in vivo animal models, and in several small clinical trials of AD patients. 15, 42, 43 Because of the promising results of clioquinol, several other 8-hydroxyquinoline analogues have been developed: PBT2 (structure not disclosed to date), 44, 45 M-30 (5-((methyl(prop-2-ynyl)-amino)methyl)quinolin-8-ol), 46 ,47 VK-28 5-((4-(2-hydroxyethyl)-piperazin-1-yl)methyl)quinolin-8-ol), 46 HLA-20 (5-((4-(prop-2-ynyl)piperazin-1-yl)methyl)quinolin-8-ol), 46 deferasirox (4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid), [46] [47] [48] deferiprone (3-hydroxy-1,2-dimethylpyridin-4(1H)-one), 49 feralex (2-(3-hydroxy-2-methyl-4-oxo-3,4-dihydropyridin-1(2H)-yl)-N-((3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxylmethyl)-tetrahydro-2H-pyran-3-yl)acetamide, 50 ,51 D-penacillamine ((S)-2-amino-3-mercapto-3-methylbutanoic acid), 52 *To whom correspondence should be addressed. Phone: 402-559-9261. Fax: 402-559-9543. E-mail: pkador@unmc.edu.
a Abbreviations: AD, Alzheimer's dementia; AMD, age-related macular degeneration; BSA, bovine serum albumin; CHL, chelating groups; FRS, free radical scavenger groups; hLECs, human lens epithelium cells; HA-h, human hippocampal astrocytes; ROS, reactive oxygen; SDI, sorbitol dehydrogenase inhibitor. DP-109 (3,3 0 -(2,2 0 -(ethane-1,2-diylbis(oxy))-bis(2,1-phenylene))-bis(5-(2-(octadecyloxy)ethoxy)-5-oxopentanoic acid), 53 and (-)-epigallocatechin 3-gallate (EGCG) ((2R,3R)-5,7-dihydroxy-2-(3, 4,5-trihydroxyphenyl)chroman-3-yl-3,4,5-trihydroxybenzoate). 54 To date, many research efforts on the treatment of ROSlinked complications have focused on therapeutic targets that enhance cellular antioxidant defenses, demonstrate antioxidant activity, or regulate cellular levels of transition metal ions. 43, 55 Because multiple mechanisms are involved in the development of ROS-linked disorders, drugs with at least two mechanisms of action targeted at ROS may offer more therapeutic benefit than those only targeting a single mechanism. Toward this end, we have synthesized a series of multifunctional analogues of N,N-dimethyl-4-(pyrimidin-2-yl)-piperazine-1-sulfonamide (1) (Figure 2 ) possessing a FRS group, (analogues 2, 6), CHL groups (CHL, analogues 3, 7), or both (analogues 4, 8). 56 The ring structure of the parent compound 1 was derived from studies investigating the effect of sorbitol dehydrogenase inhibitors (SDI) on sugar cataract formation. 57 FRS activity was introduced to 1 by addition of an -OH group in the 5-position of the pyrimidine ring. This was based on a report that 5-pyrimidinols are more effective antioxidants than their corresponding phenols, with 2-N,Ndimethyl-4,6-dimethyl-5-hydroxypyrimidine being 5-fold more reactive toward alkyl radicals and essentially equally reactive to peroxy radicals compared to R-tocopherol. 58 Methoxy groups, rather than methyl groups, were added to the pyrimidine ring because methoxy groups stabilize the radical scavenger slightly better than the methyl groups and are not as readily subjected to metabolic oxidation as the methyl groups. [59] [60] [61] The ability to chelate was introduced by adding carbonyl groups directly adjacent to the amino group connecting the piperazine ring to the pyrimidine ring. This was based on a report that 2-N-succinamide-1,3-pyrimidine easily forms complexes with transition metals such as Fe 3þ and Cu 2þ . 62 
Chemistry
Compounds 1, 5, and 6 were synthesized as outlined in Scheme 1. N,N-Dimethylpiperazine-1-sulfonamide 10 was obtained from commercially available piperazine 9 according to the literature. 63 Nucleophilic substitution of 2-chloropyrimidines 11a and 11b with N,N-dimethylpiperazine-1-sulfonamide 10 gave 1 and 5, respectively. Compound 6 was obtained through directed hydroxylation of 5. The aromatic anion of 5, which was generated in the presence of n-BuLi, was treated with oxygen gas to give 6.
64
The 5-hydroxypyrimidine analogue 2 was also initially obtained by nucleophilic substitution of 2-chloro-5-hydroxypyrimidine (15) with N,N-dimethylpiperazine-1-sulfonamide (10) (Scheme 2). Compound 15 was obtained from commercially available 2-chloro-5-nitropyrimidine (12) by first reducing the nitro group to 2-chloro-5-aminoprimidine (13) by refluxing with acetic acid in the presence of iron. Subsequent diazotization of the amine 13 failed; however, 2-chloro-5-hydroxypyrimidine 15 could be obtained in poor yield (33%) by refluxing 13 with 2 M sulfuric acid.
Because of the poor yield in obtaining 15, an alternative approach to compound 2 was employed. As outlined in Scheme 3, an initial nucleophilic reaction of N,N-dimethylpiperazine-1-sulfonamide 10 with 2-chloro-5-nitropyrimidine 12 gave the nitro product 16 which was reduced to the amine 17 by refluxing with NH 4 Cl and iron. Refluxing amine 17 with 2 M sulfuric acid gave 2 in 56% yield.
The piperazine-2,6-dione containing analogues were synthesized by condensation of 2,2 0 -(N,N-dimethylsulfamoylazanediyl)diacetic acid (19) , obtained from commercially available iminodiacetic acid (2,2 0 -azanediyldiacetic acid) (18) , with primary aromatic amines 20a-d (Scheme 4). The piperazine-2,6-diones 3, 7, 21, and 22, respectively, were obtained by activation of the 2,2 0 -(N,N-dimethylsulfamoyliminodiacetic acid (19) with acetic anhydride (step b), addition of 20a-d (step c), and subsequent dehydration (step d). 66 The benzyl protecting groups of 21 and 22 were removed by hydrogenolysis to give final 4 and 8, respectively. Compounds 20a and 20b were commercially available.
To obtain compound 4, the synthesis outlined in Scheme 5 was initially employed. The methoxy 24 was obtained in 60% yield in a three-step pot reaction from 19 and 23 according to published procedures. 67 However, attempts at selectively cleaving the methoxy group of 24 failed. In the presence of BBr 3 , a number of cleavage products were obtained, presumably because of the instability of 2,6-dioxopiperazine in the presence of the strong Lewis acid. Alternatively, no reaction was observed with mild treatment of 24 with TMSI for 12 h. Condensation of 19 with 2-amino-5-hydroxypyrimidine, 25, the cleaved methoxy product of 23, also did not result in the anticipated amide 27 (Scheme 6). Instead, ester 26 was formed because the 5-hydroxyl group of 2-amino-5-hydroxypyrimidine, 25, is more reactive; however, protection of the hydroxyl group with an easily removable benzyl group gave amine 20c which when condensed yielded compound 21. Subsequent hydrogenolysis of 21 gave the desired compound 4.
2-Amino-5-(benzyloxy)-4,6-dimethoxypyrimidine (20d) was obtained from commercially available 2-chloro-4,6-dimethoxypyrimidine 11b (Scheme 7). Oxidation of the aromatic anion of 11b generated in the presence of dioxygen gave the hydroxyl 28 in 44% yield. This yield was increased to 94% when dioxygen was replaced with lithium tert-butyl peroxide which was generated in situ from tert-butylperoxy alcohol and n-butyllithium. 68 Following benzylation of the hydroxyl group, the 2-chlorine atom was replaced with an amino group. Attempted substitution of the chlorine with an ammoniamethanol solution or ammonia hydroxide was unsuccessful. Refluxing chloride 29 in toluene with benzylamine resulted in the formation of the 2-benzyllamine 30 in 33% yield and a 64% yield (according to the procedure for preparation of compound 30) with 25% recovery of chloride 29. Replacing toluene with dioxane increased the yield of 30 to 55% with 25% recovery of 29. Attempted selective hydrogenolysis of 30 for 2 h at room temperature and 1 atm resulted in 2-benzylamino-4,6-dimethoxy-5-hydroxyprimidine in 90% yield and 2-amino-4,6-dimethoxy-5-hydroxyprimidine 31 in 10% yield. Both benzyl groups were removed to give 31 in 98% yield when hydrogenolysis was increased to 12 h. The benzyl group was Table 1 summarizes the relative percent parent peak observed with a 10:1 metal ion/compound solution for each compound. Under these conditions, a relative decrease in compound parent peak height only occurs with increased ion binding. This is illustrated in Figure 3 where the parent peak heights of compounds 1 and 3 are compared. Only compound 3 which contains the necessary piperazine-2,6-dione groups required for ion binding shows a decrease in peak height with increasing concentration of Fe ; therefore, no stoichiometry could be obtained for these compounds or ions. This was consistent with the ESI-MS data. Binding stoichiometry for compounds 3, 4, 6, and 7, summarized in Table 2 , was determined to be 1 metal chelator/2 metal ions for those ions with a tetrahedral/ square planar geometry (Cu 1þ , Cu 2þ , Zn 2þ ) or to be 2 metal chelators/1 metal ion for ions having an octahedral geometry (Fe 2þ , Fe 3þ ). This stoichiometry was consistent with the data of a similar chelating moiety in 2-(N-succinimidyl) pyrimidine. 62 In Vitro Evaluation of Antioxidant Activity. Compounds 1-8 were evaluated for their ability to protect SRA-1 human lens epithelium cells (hLECs), 69 commercially available ARPE-19 human retinal pigmented epithelial cells (RPEs), 70 and HA-h human hippocampal astrocytes (HA-hs). These three cells types are instrumental in the development of cataract, AMD, and AD, respectively.
In the first set of studies, the ability of compounds 1-8 to protect cells against ROS-induced cell death was evaluated using a MTS Cell Viability assay. The results were compared to the protective activity of the water-soluble vitamin E analogue 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid. All cells were exposed for 2 h of either 1.0 mM H 2 O 2 or Fenton reagents (1.0 mM H 2 O 2 and 1.0 mM Fe 2þ ) with/without 1 mM compounds 1-8 or 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid. As summarized in Figure 5A , the presence of H 2 O 2 , reduced the viability of the hLECs to less that 50%. A similar loss of cell viability was observed for compounds 1, 3, 5, and 7, analogues not possessing the 2-amino-5-hydroxy-1,3-pyrimidine group required for FRS activity. 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid significantly protected cell viability against ROS, and similar protection was also observed with compounds 2, 4, 6, and 8; all compounds possess the 2-amino-5-hydroxy-1,3-pyrimidine FRS group. When ROS was generated by the Fenton reaction ( Figure 5B ), in addition to the FRS containing compounds 2, 4, 6, and 8, some protection was now also demonstrated with compounds 3 and 7 which contain the 2,8-dioxopiperazine CHL group. Moreover, the multifunctional compounds possessing both FRS and CHL groups (compounds 4 and 8) demonstrated better protection than 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid. Similar results were observed for the RPE and HA-h cells. The protection afforded by compounds 1-8 against Fenton's reagent is summarized in Figure 5C and Figure 5D , respectively.
In these three cell types, the rapid intracellular reduction of cellular glutathione (GSH) is a sensitive marker of oxidative stress. As illustrated in Figure 6A , the presence of 1 mM H 2 O 2 rapidly resulted in a reduction of GSH levels in hLECs and a similar reduction was also observed with compounds 1, 3, 5, and 7, analogues not possessing the FRS group. However, GSH levels were maintained when similar cells were treated with either the water-soluble vitamin E analogue 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid or compounds 2, 4, 6, and 8 which possess the FRS group. All compounds possess the 2-amino-5-hydroxy-1,3-pyrimidine FRS group. With Fenton generated ROS ( Figure 6B ), protection was also afforded by the CHL containing compounds 3 and 7. In addition, the multifunctional compounds possessing both FRS and CHL groups (compounds 4 and 8) demonstrated slightly better protection than 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid. Again, similar results were observed for the RPE and HA-h cells. The protection afforded by compounds 1-8 against Fenton's reagent is summarized in Figure 6C and Figure 6D , respectively.
Experimental Section
NMR spectra were obtained with a Varian 500 MHz spectrometer. EI-MS utilized an Agilent 5973N MSD, and ESI-MS was conducted with a Finnigan MAT LCQ. UV-visible spectra were measured on a Molecular Devices SpectraMax Plus 384 microplate spectrophotometer (Molecular Devices, Sunnyvale, CA). Melting points were uncorrected. Column chromatography (CC) utilized Merck silica gel (230-400 mesh). Final compound purities were assessed as g99% and intermediate compound purities were assessed as g96% by reverse phase HPLC using a 250 mm Â 4.6 mm C18 Luna column (5 μ100 Å ) with a mobile phase of 75:25 methanol/water at a flow rate of 0.9 mL/min and detection at 220, 254, and 280 nm. Elemental analyses were performed by M-H-W Laboratories, Phoenix, AZ. N,N 0 -Dimethylsulfamoylpiperazine (10). 1 was obtained according to the literature. 63 General Procedure for the Preparation of N,N 0 -Dimethyl-4-(pyrimidin-2-yl)piperazine-1-sulfonamide (1) and 4-(4,6-dimethoxypyrimidin-2-yl)-N,N 0 -Dimethylpiperazine-1-sulfonamide (5). Et 3 N (0.73 mL, 5.2 mmol) was added to 1.0 g of N,N 0 -dimethylsulfamoylpiperazine 10 (5.2 mmol) dissolved in 20 mL of THF. 2-Chloro-4,6-dimethoxypyrimidine 11a (0.9 g, 5.2 mmol) dissolved in 5 mL of THF was then added, and the mixture was refluxed with stirring for 40 h. After the mixture was cooled, THF was removed under vacuum and the remaining yellow solid was dissolved in 300 mL of CHCl 3 , washed with 0.5 N HCl, water, and brine, dried over Na 2 SO 4 , and filtered. Removal of solvent and CC with 1:1 CHCl 3 /hexane gave 1.4 g (81%) of white compound 1, mp 157-158°C. 1 
4-(5-Hydroxy-4,6-dimethoxypyrimidin-2-yl)-N,N
0 -dimethylpiperazine-1-sulfonamide (6). To a solution of compound 5 (1.66 g, 5 mmol) in 40 mL of THF at -78°C and under an Ar atmosphere was added 0.3 mL of n-BuLi (7 mmol). After the mixture was stirred for 3 h at -60°C, the Ar atmosphere was replaced with oxygen. The reaction mixture was then gradually warmed to room temperature (RT), and stirring was continued for an additional 6 h. After adjusting the pH to 6-7 with dilute HCl, THF was removed by evaporation and the remaining aqueous layer was extracted with CHCl 3. The CHCl 3 layers were washed with brine, dried over Na 2 SO 4 , and filtered. Solvent evaporation gave a yellow solid, which was purified by CC with 1:1:2 CHCl 3 / EtOAc/hexane to yield 530 mg (30%) of compound 6, mp 113-114°C. The structure was confirmed by N,N-Dimethyl-4-(5-nitropyrimidin-2-yl)piperazine-1-sulfonamide (16). Triethylamine (7.2 mL, 51.8 mmol) was added to a solution of 10 (10 g, 51.8 mmol) dissolved in 400 mL of THF. 2-Chloro-5-nitropyrimidine 12 (7.7 g, 48.3 mmol) dissolved in 20 mL of THF was added to the stirred mixture. After the mixture was stirred for 24 h at RT, THF was removed under vacuum and 600 mL of CHCl 3 was added to the residue. The CHCl 3 layer was washed with 0.5 N HCl, water, and brine, dried over Na 2 SO 4 , and filtered. Solvent evaporation gave 14.1 g (92%) of straw-yellow solid 16. H 2 O (48 mL), followed by iron powder (7.5 g, 133.9 mmol). After refluxing 1 h, the reaction mixture was filtered and concentrated to give a brown solid which was dissolved in 800 mL of CHCl 3 , washed with NaHCO 3 and brine, dried over Na 2 SO 4 , and filtered. Solvent evaporation gave a yellow solid which after CC with 100:1 CHCl 3 /MeOH gave 11.5 g (90%) of solid yellow 17. 2 mmol) in 100 mL of 2 M H 2 SO 4 was refluxed for 1.5 h until the suspension became clear. After the mixture was cooled to RT, the solution pH was adjusted to 6-7 with 10 N NaOH, and the cloudy mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na 2 SO 4 , and filtered. Solvent evaporation gave a yellow solid, which was purified by CC using 1:1 EtOAc/ hexane to yield 3.23 g (56%) of white solid compound 2, mp 134-135°C. 5-Hydroxy-2-aminopyrimidine (25) . Under argon at RT, BBr 3 (2.6 mL, 50 mmol) was added dropwise to a solution of 23 (1.25 g, 10 mmol) in 60 mL of benzene, and the mixture was refluxed for 6 h. After the mixture stood overnight at RT, the solvent was evaporated and the residue was carefully treated with 10 mL of ice cold H 2 O. The pH of the solution was adjusted to 6-7 with 6 N NaOH and then extracted with EtOAc. The EtOAc layers were washed with brine, dried over Na 2 SO 4 , and filtered. Solvent evaporation gave a yellow solid, which after CC using 20:1 CHCl 3 /MeOH gave 840 mg (75%) of white solid 5-hydroxy-2-aminopyrimidine 25. 
. 5-Benzyloxy-2-aminopyrimidine (20c). K 2 CO 3 (276 mg, 2 mmol) was added to 222 mg of 25 (2 mmol) in 5 mL of methanol, followed by BnBr (0.24 mL, 2 mmol). After the mixture was stirred for 14 h at RT, the reaction was stopped by addition of water. Methanol was evaporated. The remaining aqueous layer was extracted with CHCl 3 . The combined CHCl 3 layers were washed with brine, dried over Na 2 SO 4 , and filtered. Removal of the solvent followed by CC using 67:1 CHCl 3 /MeOH yielded 300 mg (75%) of white solid 20c.
1 H NMR (CDCl 3 ) δ 8.08 (s, 2H), 7.40-7.32 (m, 5H), 5.03 (s, 2H), 4.77 (br s, 2H).
2-Chloro-5-hydroxy-4,6-dimethoxypyrimidine (28). To a stirred suspension of 10.44 g 2-chloro-4,6-dimethoxypyrimidine 11b, (60 mmol) in 200 mL of THF under argon at -78°C was added dropwise a solution of LDA (2 M in THF/heptane/ethyl benzene, 60 mL, 120 mmol). To a separate round-bottomed flask at -78°C under argon containing tert-butyl hydroperoxide (5.5 M in decane, 22.7 mL,125 mmol) in 150 mL of THF was added a solution of n-BuLi (1.6 M in hexane, 78 mL, 125 mmol). Then, after being stirred for 1 h, the hydroperoxide anion solution was added via a double-ended needle to the aromatic anion. The temperature was gradually raised to 0°C, with stirring continuing an additional 3 h. The reaction was quenched with 6 N HCl until a pH of 7 was obtained. After THF evaporation the remaining aqueous layer was extracted with CHCl 3 . The CHCl 3 layers were washed with brine, dried over Na 2 SO 4 , and filtered. Removal of solvent and subsequent purification by CC using 100:1 CHCl 3 /MeOH gave 10.67 g (93.4%) of white solid 28. (29) . K 2 CO 3 (10.0 g, 70 mmol) was added to 28 (13.24 g, 69.5 mmol) dissolved in 200 mL of MeCN followed by BnBr (8.3 mL, 69.5 mmol). After the mixture was stirred for 14 h at RT, the reaction was stopped by addition of water. MeCN was evaporated, the remaining aqueous layer was extracted with CHCl 3 . The combined CHCl 3 layers were washed with brine, dried over Na 2 SO 4 , and filtered. Removal of the solvent followed by CC using 25:1 hexane/EtOAc gave 16.57 g (85%) of benzyloxy 29. CDCl 3 ) δ 7.41-7.31 (m, 5H) N-Benzyl-5-(benzyloxy)-4,6-dimethoxypyrimidin-2-amine (30). A mixture of 29 (3.18 g, 11.33 mmol), BnNH 2 (2.2 mL, 20 mmol), and K 2 CO 3 (1.66 g, 12 mmol) in dioxane (60 mL) was refluxed for 4 days. The mixture was filtered and the filtrate concentrated in vacuo to give a yellow oil, which after CC with 25:1 to 10:1 hexane/EtOAc gave 2.54 g (64%) of white solid 30. 3 mmol) in MeOH (240 mL) was added K 2 CO 3 (3.5 g, 25 mmol), followed by BnBr (3.0 mL, 25 mmol). After the mixture was stirred for 12 h at RT, water was added to the reaction mixture. MeOH was evaporated, and the water layer was extracted with CHCl 3 . The combined CHCl 3 layers were washed with brine, dried over Na 2 SO 4 , and filtered. Removal of CHCl 3 gave a yellow solid, which after purification by CC with 10:1 to 2:1 hexane/EtOAc yielded 5.14 g (81%) of 2-amine-4,6-dimethoxy-5-benzyloxypyrimidine 20d. General Procedure for Preparation of 4-(5-Hydroxypyrimidin-2-yl)-N,N-dimethyl-3,5-dioxopiperazine-1-sulfonamide (4) and 4-(5-Hydroxy-4,6-dimethoxypyrimidin-2-yl)-N,N-dimethyl-3,5-dioxopiperazine-1-sulfonamide (8). Compound 21 (2.0 g, 4.9 mmol) dissolved in 100 mL of EtOAc was hydrogenated with 500 mg of 10% Pd/C catalyst at RT for 12 h. After filtration and solvent evaporation, compound 4 recrystallized from EtOAc to give 1.83 g (80%) of a white powder, mp 225-226°C. , Zn 2þ , Ca 2þ , and Mg 2þ was determined using the method of continuous variation (Job plots). 72 Because of their low solubility, compounds 1-8 were first dissolved in acetonitrile (HPLC grade). These concentrated solutions were then diluted to 0.1 mM stock solutions with 1 mM acetate (pH 6.5). In a typical experiment (at 23°C), several solutions of the compound and metal ion of interest were prepared at a constant total concentration of compound and ion but with a different mole fraction of one component. After an equilibration period of 45 min, the change in UV absorbance was monitored from 210 to 310 nm. The maximum absorbance for each compound was then recorded as a function of the mole fraction of the metal ion. Two linear dependences were obtained, at low and high molar fractions, which intersect at a mole fraction value that corresponds to the stoichiometry of the complex.
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Cell Culture Studies. Human lens epithelial cells (SRA-1), obtained as a gift from Dr. Reddy, 69 were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 4 mM L-glutamine, 1.5 g/L NaHCO 3 , and 1% penicillin/streptomycin solution. Human retinal pigmented epithelial cells (ARPE-19), obtained from the American Type Culture Collection (Manassas, VA), were cultured in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 (DMEM/F12) medium with 2.5 mM L-glutamine and 15 mM HEPES buffer (Gibco, Carlsbad, CA) containing 10% heat-inactivated FBS and 1% penicillin/streptavidin solution. Human hippocampal astrocytes (HA-h), obtained from the ScienCell Research Laboratories (Carlsbad, CA), were cultured on poly-L-lysine coated containers (2 μg/cm 2 ) with astrocyte medium (ScienCell, Carlsbad, CA) composed of 500 mL of basal medium, 5 mL of astrocyte growth supplement, and 5 mL of penicillin/streptomycin solution. All cells were cultured at 37°C in a humidified atmosphere of 5% CO 2 and 95% air until subconfluent (2-4 days). Cells were passaged when 80-90% confluent by treatment with trypsin-EDTA and then plated at a density of 1 Â 10 4 cells onto 96-well plates or 1 Â 10 6 cells onto 150 mm dishes. For compound evaluation, FBS-free media (blank and control) or FBS-free media containing either 100 μM compounds 1-8 or 100 μM water-soluble vitamin E analogue 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) were added to each individual well/dish. After 1 h, an additional aliquot of FBS-free media was added to the blank well/dish, and a similar volume of FBS-free media containing 1 mM H 2 O 2 was added to all remaining wells/dishes. For the Fenton studies, addition of H 2 O 2 was immediately followed by addition of 1 mM ammonium iron(II) sulfate hexahydrate. After 2 h of exposure, all media were removed and the cells were washed at room temperature with PBS. All studies were conducted in triplicate.
Cell viability studies were conducted in 96-well plates using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS, Promega, Madison, WI). Briefly, after 2 h of exposure to either H 2 O 2 or Fenton reagents, media were removed from all wells and each well was washed with PBS. After removal of the PBS wash, 100 μL of blank media was added to each well followed by addition of 20 μL of the MTS solution. The cells were further incubated at 37°C for 1.5 h and then spectrophotometrically evaluated at 490 nm in a plate reader. The results were normalized to blank control (100%) of cells not treated with H 2 O 2 .
GSH measurements were conducted on cells cultured in either 100 or 150 mm dishes. After 2 h of exposure to either H 2 O 2 or Fenton reagents, the media were removed and the cells were washed with PBS. The cells were removed from each dish by scraping and homogenized in glass homogenizers. Following centrifugation at 4°C, protein levels in the supernatant were measured according to Bradford. 73 The cell homogenates were then deproteinized with equal volumes of 20% trichloroacetic acid (TCA), and GSH levels were measured at 412 nm according to the DTNB method. 74 GSH levels were expressed as nmol of GSH/mg of protein, with values subsequently normalized to GSH levels in cells not exposed to H 2 O 2 (blank control, 100%).
